#Switzerland #Zurich #Polaroid Therapeutics #POLTX_Fiber™ #APT™

Polaroid Therapeutics' Breakthrough in Wound Care

In a significant development for the healthcare sector, Polaroid Therapeutics (PTx) has announced that its innovative product, POLTX_Fiber™, has received the CE mark as a Class IIb medical device. This certification is a milestone for PTx as it seeks to redefine standards in wound care through advanced antimicrobial technology known as Antimicrobial Polymer Technology (APT™).

POLTX_Fiber™ stands out as the first product from Polaroid Therapeutics and is designed as a gelled antimicrobial dressing that incorporates APT™. This new platform is aimed at promoting better wound management by preventing bacterial colonization within the dressing itself, addressing a critical concern in modern medical care without contributing to antimicrobial resistance.

The Technology Behind POLTX_Fiber™

The innovative dressing is made from sodium carboxymethylcellulose (CMC) and reinforcing cellulose fibers, allowing it to form a protective gel upon contact with wound exudate. This gel helps maintain a moist environment conducive for healing while also promoting autolytic debridement. The unique design ensures that the surrounding skin and the wound edges are shielded from excessive moisture, which could lead to maceration.

Versatile Application

Under the guidance of healthcare professionals, POLTX_Fiber™ is suitable for treating a wide range of wounds, including:

• - Moderate to heavy exudating wounds
• - Acute and chronic wounds
• - Leg ulcers, pressure sores (stage II-IV), and diabetic ulcers
• - Surgical wounds, including post-operative sites
• - Traumatic wounds such as abrasions and lacerations
• - Exudative oncological wounds
• - Superficial or cavity wounds

According to Ran Frenkel, co-founder and CEO of Polaroid Therapeutics, achieving the CE mark is a major leap forward for the company. He states, "We aspire to provide better patient care options through human-centered solutions driven by cutting-edge technology and scientific advancements. POLTX_Fiber™ is our first medical device that showcases our APT™ platform, integrating a novel antimicrobial polymer technology that adheres to the strictest standards while tackling the real challenges in modern wound care. This certification opens up new treatment avenues, ensuring we set a new standard in care and protection."

A Promising Future in Wound Care

As PTx moves forward post-CE certification, the company plans to introduce POLTX_Fiber™ to select European markets, collaborating with clinicians, wound care centers, and distribution partners to foster clinical experience and patient outcomes.

POLTX_Fiber™ is not just the beginning; it represents the first step in a broader product portfolio that will harness APT™ technology. Polaroid Therapeutics is actively developing additional medical devices intended to expand the applications of this platform across various healthcare contexts.

About Polaroid Therapeutics

Founded in 2022 and based in Switzerland, Polaroid Therapeutics (PTx) is a biotechnology startup focused on redefining medical solutions with its innovative antimicrobial technology. Its APT™ platform is engineered to control antimicrobial performance through structural design rather than chemical release, emphasizing responsible innovation and the regulated evidence behind its products.

With a commitment to addressing antimicrobial resistance through long-term management, PTx develops solutions that are not only effective but also fit seamlessly into modern healthcare practices.

Conclusion

In conclusion, POLTX_Fiber™ marks a transformative advancement in wound care technology. As Polaroid Therapeutics prepares for market introduction, the healthcare community awaits eagerly to see how this innovative dressing will impact patient care and set new benchmarks in the industry.